Trial CA224-047

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial

Trial acronym

CA224-047

Full title

A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma Z:339

Responsible organization

3. Med 3. Med Ismaninger Str. 22 81675 München Germany

Indications

Classification	Code	Description
-		Skincancers

Trial design

Phase

II/III

Status

Recruitment finished

Votes

Initiiation & lock

Date of lock (planned / actual)

Unknown / Unknown

Therapy

Therapy line

Therapy

Zielgerichtet

Participants

	Function	Prename	Surname	Organization
	Responsible contact	Folker	Schneller	3. Med 3. Med Ismaninger Str. 22 81675 München Germany